临床肝胆病杂志2017，Vol.33Issue(5)：998-1002,5.DOI:10.3969/j.issn.1001-5256.2017.05.044
原发性胆汁性胆管炎的药物治疗新靶点
Novel therapeutic targets for primary biliary cholangitis
陈荣彬 1吴学铭 1吴颖 1姚定康1
作者信息
- 1. 第二军医大学第二附属医院,上海200003
- 折叠
摘要
Abstract
Primary biliary cholangitis (PBC) is a chronic autoimmune-mediated liver disease manifesting as progressive cholestasis and non-purulent inflammation in small-and medium-sized intrahepatic bile ducts.It finally progresses to liver cirrhosis and liver cancer and greatly threatens patient~ life.Studies have found that ursodeoxycholic acid (UDCA) can treat PBC effectively.There is a constant increase in the proportion of patients with poor response to UDCA who have undergone transplantation or died,and therefore,new therapeutic regimens should be developed as soon as possible.It is necessary to develop new drugs which act on the key processes of disease progression,such as the "upstream" immune response,the "midstream" bile duct injury,and the "downstream" fibrotic process.Combination treatment with drugs targeting different pathways is a trend for future development.This article summarizes current potential therapeutic regimens for PBC and assesses the challenges in the treatment of PBC.关键词
肝硬化,胆汁性/治疗/综述Key words
liver cirrhosis, biliary/therapy/review分类
医药卫生引用本文复制引用
陈荣彬,吴学铭,吴颖,姚定康..原发性胆汁性胆管炎的药物治疗新靶点[J].临床肝胆病杂志,2017,33(5):998-1002,5.
